India’s pharma recalls trigger global scrutiny as regulators tighten quality oversight

India’s pharmaceutical recalls are drawing global attention, as the US Food and Drug Administration (FDA) recently announced a nationwide recall of over 140,000 bottles of Indian-made atorvastatin, a widely prescribed cholesterol-lowering drug.

While the development underscores both the scale of India’s role in global medicine supply, it also turns the spotlight on the risks of quality lapses, reports The Pharma Letter’s India correspondent.

The clustering of recent recalls suggests systemic challenges in quality assurance across multiple Indian pharmaceutical manufacturers. Regulatory pressure is building up and the USFDA is expected to intensify inspections of Indian facilities, potentially delaying approvals and raising compliance costs.